BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16491292)

  • 1. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.
    Middleton-Hardie C; Zhu Q; Cundy H; Lin JM; Callon K; Tong PC; Xu J; Grey A; Cornish J; Naot D
    J Bone Miner Res; 2006 Mar; 21(3):438-45. PubMed ID: 16491292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
    Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
    Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
    Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone.
    Salmon P
    J Bone Miner Res; 2004 May; 19(5):695-702. PubMed ID: 15068491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
    J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
    Whyte MP
    Ann N Y Acad Sci; 2006 Apr; 1068():143-64. PubMed ID: 16831914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
    Yamada N; Tsujimura T; Ueda H; Hayashi S; Ohyama H; Okamura H; Terada N
    Cytokine; 2005 Aug; 31(4):288-97. PubMed ID: 15996478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
    J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.
    Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP
    J Bone Miner Res; 2005 Jan; 20(1):30-40. PubMed ID: 15619667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
    J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
    Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
    J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
    Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
    J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype.
    Chong B; Hegde M; Fawkner M; Simonet S; Cassinelli H; Coker M; Kanis J; Seidel J; Tau C; Tüysüz B; Yüksel B; Love D;
    J Bone Miner Res; 2003 Dec; 18(12):2095-104. PubMed ID: 14672344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels.
    Whyte MP; Singhellakis PN; Petersen MB; Davies M; Totty WG; Mumm S
    J Bone Miner Res; 2007 Jun; 22(6):938-46. PubMed ID: 17352649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.